Navigation Links
Breast cancer drug shows promise for treating, preventing progestin-dependent tumors
Date:1/28/2009

COLUMBIA, Mo. Recent studies suggest that human breast cancer risk is increased by outside exposure to the hormone progestin, such as during hormone replacement therapy. Now, a University of Missouri study suggests that PRIMA-1, a small molecule drug that targets the most common mutated gene, p53, in human cancer cells, has potential as a novel chemotherapeutic treatment for progestin-accelerated human breast cancer.

"We demonstrated that PRIMA-1 was an effective drug to treat and prevent emergence of progestin-accelerated mammary tumors in rats," said Salman Hyder, professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center. "The results of this study may have significant implications for the treatment and prevention of human breast cancer because such a large fraction of human breast cancers are dependent on estrogens and progestins for growth."

Mutated p53 plays a key role in promoting tumor cell survival and tumor cell resistance to chemotherapeutic drugs. In more than 50 percent of breast cancer cases, mutated p53 is present. Previous research has indicated that when p53 is functionally abnormal, tumor cells are prolific and develop quickly. PRIMA-1 targets and returns normal function to the mutated p53.

In the study, researchers examined the ability of PRIMA-1 to suppress growth of progestin-accelerated, mammary tumors in an animal model. When tumors reached a certain size, researchers administrated PRIMA-1 twice a day for three days. The researchers found that PRIMA-1 caused regression of approximately 40 percent of progestin-accelerated mammary tumors. However, the drug did not induce regression of native, non-progestin accelerated tumors. PRIMA-1 also suppressed the emergence of any new progestin-accelerated tumors in the animal model.

"Postmenopausal women worldwide are exposed to exogenous progestin in the form of hormone replacement therapy, and clinical studies have associated combined exposure to progestin and estrogen with an increased incidence of human breast cancer in this population," said Hyder, who is also the Zalk Endowed Professor of Tumor Angiogenesis. "Because PRIMA-1 blocked the formation of new tumors following progestin stimulation in this experimental model, it is tempting to speculate that this agent could be used to prevent progestin-accelerated tumors in women on hormone replacement therapy. However, this needs to be tested thoroughly in a clinical setting."


'/>"/>

Contact: Kelsey Jackson
JacksonKN@missouri.edu
573-882-8353
University of Missouri-Columbia
Source:Eurekalert

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Illinois (PRWEB) , ... May 26, 2016 , ... ... with women’s basketball as a partner for the Tamika Catchings Legacy Tour ... As the industry leader in hardwood basketball surfaces in all forms and levels of ...
(Date:5/26/2016)... ... 2016 , ... The Woodlands at John Knox Village , Florida’s first ... for living and healing, celebrated its grand opening, today. The Woodlands at John Knox ... by Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village ...
(Date:5/26/2016)... TN (PRWEB) , ... May 26, 2016 , ... There ... and more than 32 million cancer survivors worldwide. On Sunday, June 5, 2016, communities ... 29th annual National Cancer Survivors Day®. , National Cancer Survivors Day® is an ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma ... drugs, biologics, consumer health and global clinical supply services, today announced two key ... the company’s continued investment and strategic growth plans in the Asia Pacific region. ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising health care ... of Sun Health Senior Living (SHSL) may not share those same worries ... prescription copays for the year, while holding the line on increasing their contributions, including ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... CHRISTCHURCH, New Zealand , May 24, 2016 ... scanning and informatics solutions for the healthcare sector, has been ... the New Zealand Hi-Tech Awards 2016. Dr ... a fantastic acknowledgement for our team.  It,s really good to ... the burden healthcare internationally. Our products are used in 35 ...
(Date:5/24/2016)... -- The innovator of COMBO ... s first dual therapy stent, introduces catheters for lower ... a global company specializing in the provision of life-changing ... to treat peripheral artery disease. The JADE™ and Scoreflex™ ... lower limb and arteriovenous (AV) fistula intervention. ...
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to help ... on a global scale. Medical professionals from Europe ... and the US have already signed up for the app, which ... secure environment. Education  "Imagine a doctor for ... surgeon at Harvard to treat a bomb victim via live streaming ...
Breaking Medicine Technology: